156 related articles for article (PubMed ID: 23613475)
1. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
2. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
[TBL] [Abstract][Full Text] [Related]
3. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
4. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
[No Abstract] [Full Text] [Related]
5. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
6. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
[No Abstract] [Full Text] [Related]
7. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Sibaud V; Chevreau C
Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
[No Abstract] [Full Text] [Related]
8. Towards a unified model of RAF inhibitor resistance.
Solit DB; Rosen N
Cancer Discov; 2014 Jan; 4(1):27-30. PubMed ID: 24402945
[TBL] [Abstract][Full Text] [Related]
9. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
Smalley KSM; Forsyth PA
Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209
[No Abstract] [Full Text] [Related]
10. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
11. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
12. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
13. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
16. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
Gutzmer R
J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
[No Abstract] [Full Text] [Related]
17. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
18. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
19. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
20. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]